Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-10-26
1994-02-01
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 514 12, A61K 3726, A61K 3764, A61K 4700
Patent
active
052832368
ABSTRACT:
Compositions and methods for systemic delivery of polypeptides through the eyes are disclosed. The compositions include a systemically active polypeptide at a concentration such that the composition is substantially isotonic with tear fluid. The compositions may include a permeation-enhancing agent to aid systemic absorption of higher molecular weight polypeptides, as well as peptidase inhibitors. Therapeutically effective amounts of the polypeptide compositions can be administered to the eyes where the drug passes into the nasolacrimal duct and becomes absorbed into circulation.
REFERENCES:
patent: 4093709 (1978-06-01), Choi et al.
patent: 4186184 (1980-01-01), Zaffaroni
patent: 5182258 (1993-01-01), Chiou
Galloway, J. A., et al., "Factors influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures", Diabetes Care (1981) 4(3):366-376.
Monkhouse, D.C., et al., "The Effect of EDTA on the Resistance of Pseudomonas Aeruginosa to Benzalkonium Chloride", Aust. J. Pharm. (1967) 48(570):S70-S75.
Moses, A. C., "Routes of Administration: Nasal", Proceedings of Land O'Lake (1986) 86, Merrimac, WI, Lecture Note, pp. 1 10.
Mygind, N., et al, "Aerosol Distribution in the Nose", Rhinology (1978) vol. XVI, pp. 79-88.
Bito, L. Z., et al., "Transport of Prostaglandins Across the Blood-Brian and Blood Aqueous Barriers and the Physiological Significance of these Absorptive Transport Processes", Exp. Eye Research Suppl. (1977) pp. 229-243.
McClure, D. A., "The Effect of a Pro-Drug of Epinephrine (Dipivalyl Epinephrine) in Glaucoma--General Pharmacology, Toxicology, and Clinical Experience", in Pro-Drugs as Novel Drug Delivery Systems, ACS Symposium Series No. 14, Higuchi, T., et al., editors (published by American Chemical Society, Washington, D.C., 1975), pp.; 224-235.
Lee, V. H. L., et al., "Metabolic and Permeation Barriers to the Ocular Absorption of Topically Applied Enkephalins in Albino Rabbits", J. Ocular Pharmacol. (1986) 2(4):345-352.
Christie, C. D., et al., "Insulin Absorption by the Conjunctival Membranes in Rabbits", J. Clin. Invest. (1931) 10:787-793.
Ueno, N., et al., "Ocular Pharmacology of Drug Release Devices", in Controlled Drug Delivery, Vol II, Clinical Applications, Bruck, S. D., editor, (published by CRC Press, Inc., Florida, 1983), Chapter 4, pp. 89-109.
Chiou, G. C. Y., et al., "Treatment of Hypoglycemia with Glucagon Eye Drops", J. Ocular Pharmacol. (1988) 4(2):179-186.
Chiou, G. C. Y., et al., "Systemic Delivery of Enkephalin Peptide Through Eyes", Life Sciences (1988) 43(6):509-514.
Chiou, G. C. Y., et al., "Reduction of Blood Glucose Concentration with Insulin Eye Drops", Diabetes Care (1988) 11(9):750-751.
Chiou, G. C. Y., et al., "Systemic Delivery of Polypeptides with Molecular Weights of Between 300 and 3500 Through the Eyes", Journal of Ocular Pharmacology (1988) 4(2):165-177.
Chiou, G. C. Y., et al., "Systemic Delivery of Insulin Through Eyes to Lower the Glucose Concentration", J. Ocular Pharmacol. (1989) 5(1):81-91.
Saettone, M. F., et al., "Vehicle Effects in Opthalmic Bioavailablity: An Evaluation of Polymeric Inserts Containing Pilocarpine", J. Pharm. Pharamcol. (1984) 36:229-234.
Aungst, B. J., et al., "Site Dependences of Absorption-Promoting Actions of Laureth 9, Na Salicylate, Na.sub.2 EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery", Pharmaceutical Research (1988) 5(5):305-308.
Lee Pharm. Technology (Apr. 1987) pp. 28-38.
Lee Pharmacy International (Jun. 1985) pp. 135-138.
Hirai et al Int'l Journal of Pharmaceutics 9 (1981) 173-184.
Koh Choon
Orbon Corporation
Wityshyn Michael G.
LandOfFree
Systemic delivery of polypeptides through the eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systemic delivery of polypeptides through the eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic delivery of polypeptides through the eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-579907